|
Harmonizing U.S., EU Orphan Protocol Guidance Could Speed Access to Therapies
To help drugmakers speed new therapies to patients with rare diseases, U.S. and EU regulators should harmonize their philosophies around orphan drug development and generate common guidance on trial requirements, experts say.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives